International Pharmaceutical Laboratories Astrazeneca, Bayer and Boehringer Ingelheim, as well as the Mexican Laboratory Carnot, an investment of $ 600 million (516 million euros) announced Thursday in Mexico.
The pharmaceutical sector is “an absolute priority for the president (Claudia Sheinbaum), especially for its global impact” and the health of Mexicans, said economy Minister Marcelo Ebrard during the announcement together with the regional leaders of these companies.
These investments have continued those already announced in recent months by the multinational Heineken, Walmart and Netflix, in a context of commercial tensions between Mexico and the United States.
According to the Secretary of Health, David Kershenobich, these four laboratories aim to “extend their technological and production capacities and export.”
Infrastructure and Clinical Research
The German pharmaceutical giant Bayer plans to dedicate about $ 160 million in the next five years, he explained to its director for Mexico, Manuel Bravo.
Boehringer Ingelheim will invest $ 187 million for several years to make its production plant for pharmaceutical tablets in Xochimilco, south of Mexico City, “the largest in the world,” said its director of Mexico, Central America and the Caribbean, Augusto Muench.
The Astrazeneca British pharmaceutical company will improve its innovation center and its drug production units for type 2 diabetes and chronic kidney diseases in Mexico. Thanks to an investment of $ 120.7 million until 2026, Astrazeneca will also increase its clinical research activities, he explained to his local representative, Julio Ordaz.
The director of the Mexican Laboratory Carnot, Edmundo Jiménez, announced the construction of a new factory in the state of Hidalgo (center) for an amount of $ 187 million in five years.
The pharmaceutical industry undergoes pressures from the president of the United States, which requires a price drop and threatens to impose progressive customs tariffs that can reach 250 % in imports.
Source: BFM TV
